Sign in
4

Changes in Ownership

AGIOS PHARMACEUTICALS, INC. Filed Acc 0001439222-24-000142

Director sold 20,000 shares at an average $55.86 ($1,117,147)

  • Director acquired 20,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Ballal Rahul D. · Director

Table I: Non-derivative

7 lines
Date Transaction Shares Price Value Owned after D/I
2024-11-07 Exercise or conversion : show line 1 in the form 10b5-1 +10,000 $25.99 $259,900 17,992 D
2024-11-07 Sale : show line 2 in the form 10b5-1 −8,132 $53.32 $433,598 9,860 D
2024-11-07 Sale : show line 3 in the form 10b5-1 −1,868 $54.41 $101,638 7,992 D
2024-11-08 Exercise or conversion : show line 4 in the form 10b5-1 +10,000 $25.99 $259,900 17,992 D
2024-11-08 Sale : show line 5 in the form 10b5-1 −3,571 $57.24 $204,404 14,421 D
2024-11-08 Sale : show line 6 in the form 10b5-1 −4,929 $58.57 $288,692 9,492 D
2024-11-08 Sale : show line 7 in the form 10b5-1 −1,500 $59.21 $88,815 7,992 D
Open-market sales · 20,000 sh · avg $55.86 · $1,117,147

Table II: Derivative

2 lines
Date Transaction Shares Owned after D/I
2024-11-07 Exercise or conversion : show line 8 in the form 10b5-1 Stock option (right to buy) −10,000 27,947 D
2024-11-08 Exercise or conversion : show line 9 in the form 10b5-1 Stock option (right to buy) −10,000 17,947 D
Loading xslF345X05/wk-form4_1731445769.xml…